Intellia Therapeutics to Discuss Financial Results and Company Updates

CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a prominent company in clinical-stage gene editing, is preparing to share its financial results for the fourth quarter and the full year of 2024. The discussion will take place during a conference call scheduled for February 27, 2025, at 8 a.m. ET.

During the upcoming call, the company will highlight key operational achievements and financial metrics from the past year. Intellia Therapeutics is dedicated to advancing medicine through innovative CRISPR-based therapies, focusing on addressing crucial unmet medical needs.

To participate in the conference call:

• U.S. callers can dial 1-833-316-0545, while international participants should use 1-412-317-5726. It is recommended to join the call about five minutes beforehand. All attendees should ask to be connected to the Intellia Therapeutics conference call.
• A live webcast will be available, allowing for remote participation.

A recording of the call will be accessible on the Events and Presentations page within the Investors & Media section of Intellia’s website, starting on February 27, 2025, at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics, Inc. (NASDAQ:NTLA) focuses on developing revolutionary gene editing technologies, aiming to create CRISPR-based therapies that can change the treatment landscape for numerous conditions. The company draws on a wealth of scientific and clinical expertise to pioneer groundbreaking medicines that fill significant gaps in treatment. By continuously enhancing its CRISPR technology platform, Intellia is committed to unlocking the full potential of gene editing.

For more information about the company, please visit their website at intelliatx.com and follow on social media at @intelliatx.

Intellia, Earnings, Conference